The year in cardiovascular medicine 2021: dyslipidaemia

Lale Tokgozoglu, Carl Orringer, Henry N. Ginsberg, Alberico L. Catapano

Research output: Contribution to journalArticlepeer-review

Abstract

The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.

Original languageEnglish (US)
Pages (from-to)807-817
Number of pages11
JournalEuropean heart journal
Volume43
Issue number8
DOIs
StatePublished - Feb 22 2022
Externally publishedYes

Keywords

  • Antisense
  • Cardiovascular diseases
  • CRISPR
  • LDL-C. Triglycerides
  • Lipids
  • Lp(a)
  • Nucleic acid therapeutics
  • PCSK9 inhibitors
  • RNA interference
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'The year in cardiovascular medicine 2021: dyslipidaemia'. Together they form a unique fingerprint.

Cite this